NASDAQ$ATRA
Atara Biotherapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year 2021, along with business highlights and key upcoming catalysts for 2022.
Atara Biotherapeutics reported a net loss of $93.3 million for Q4 2021, with cash, cash equivalents, and short-term investments totaling $371.1 million as of December 31, 2021. The company is progressing its pipeline, including tab-cel and ATA188, but faces regulatory challenges with the FDA regarding tab-cel's BLA submission in the U.S.
- Atara's EMA filing for tab-cel is progressing as planned, with anticipated EU approval in Q4 2022 under Accelerated Assessment.
- ATA188 was granted FDA Fast Track designation in both non-active PPMS and non-active SPMS, with Phase 2 EMBOLD study interim analysis planned for Q2 2022.
- Atara entered a long-term strategic manufacturing partnership with Fujifilm, receiving an upfront cash payment of USD 100 million.
- Further engagement and alignment are required with the FDA to determine the path forward for a BLA submission in the U.S. for tab-cel.
Headline financials
Revenue & EPS history
Atara · Revenue · Quarterly
$7.55M
Forward guidance
Atara believes that its cash as of December 31, 2021, together with the anticipated $100.0 million payable to Atara upon closing of the strategic transaction with FDB, will be sufficient to fund the Company’s planned operations into the fourth quarter of 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-2.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
37%
17 / 46 earnings
Positive
+36.3%
Q2 2022
Best reaction
-24.2%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +11.5% | +9.6% | +17.2% | |
| Q4 2025 | -0.6% | -16.4% | -10.7% | |
| Q3 2025 | -1.3% | +4.3% | +43.3% | |
| Q1 2025 | +4.8% | +6.8% | +6.3% | |
| Q4 2024 | +3.9% | -9.2% | +10.6% | |
| Q3 2024 | +21.2% | +2.0% | -7.0% | |
| Q2 2024 | +5.8% | -7.5% | +9.6% | |
| Q1 2024 | -6.3% | +6.9% | -6.5% | |
| Q4 2023 | +3.6% | +4.0% | -1.4% | |
| Q3 2023 | -7.8% | +2.3% | -49.8% | |
| Q2 2023 | -16.4% | -7.1% | -31.6% | |
| Q1 2023 | -16.2% | -26.5% | -43.3% | |
| Q4 2022 | -12.6% | -18.7% | -48.2% | |
| Q3 2022 | -18.0% | +8.5% | +0.2% | |
| Q2 2022 | +36.3% | +69.8% | +32.3% | |
| Q1 2022 | -5.3% | -22.2% | -29.7% | |
| Q4 2021 | -22.6% | -32.9% | -30.4% | |
| Q3 2021 | -3.1% | -4.4% | -8.9% | |
| Q2 2021 | +0.8% | -1.5% | +17.9% | |
| Q1 2021 | -3.9% | -3.3% | -5.1% | |
| Q4 2020 | +1.0% | -4.2% | -14.4% | |
| Q3 2020 | -5.9% | +9.0% | +72.0% | |
| Q2 2020 | +1.9% | +3.5% | +4.8% | |
| Q1 2020 | +4.9% | +17.5% | +11.7% | |
| Q4 2019 | +8.8% | +11.5% | -24.4% | |
| Q3 2019 | +10.2% | +6.9% | +15.0% | |
| Q2 2019 | +10.6% | +17.3% | +16.4% | |
| Q1 2019 | -24.2% | -27.1% | -35.6% | |
| Q4 2018 | -13.3% | -8.5% | -7.4% | |
| Q3 2018 | -1.9% | -3.5% | +5.7% | |
| Q2 2018 | -2.1% | +0.5% | +9.1% | |
| Q1 2018 | -5.8% | +1.7% | +0.6% | |
| Q4 2017 | -10.6% | -8.6% | -9.5% | |
| Q3 2017 | -6.3% | -4.9% | +3.1% | |
| Q2 2017 | -3.3% | -3.6% | -1.3% | |
| Q1 2017 | -5.1% | -7.0% | -10.2% | |
| Q4 2016 | +21.4% | +16.8% | -1.2% | |
| Q3 2016 | +17.2% | +45.6% | +32.6% | |
| Q2 2016 | -9.5% | -14.7% | -14.3% | |
| Q1 2016 | -5.5% | — | — | |
| Q4 2015 | -18.5% | — | — | |
| Q3 2015 | +4.7% | — | — | |
| Q2 2015 | -11.4% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q4 2014 | -5.9% | — | — | |
| Q3 2014 | -15.5% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro